These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33578418)

  • 1. 18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome.
    Goodheart AE; Locascio JJ; Samore WR; Collins JA; Brickhouse M; Schultz A; Touroutoglou A; Johnson KA; Frosch MP; Growdon JH; Dickerson BC; Gomperts SN
    Brain; 2021 Feb; 144(1):266-277. PubMed ID: 33578418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.
    Xia C; Makaretz SJ; Caso C; McGinnis S; Gomperts SN; Sepulcre J; Gomez-Isla T; Hyman BT; Schultz A; Vasdev N; Johnson KA; Dickerson BC
    JAMA Neurol; 2017 Apr; 74(4):427-436. PubMed ID: 28241163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study.
    Holland N; Malpetti M; Rittman T; Mak EE; Passamonti L; Kaalund SS; Hezemans FH; Jones PS; Savulich G; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2022 Mar; 145(1):340-348. PubMed ID: 34398211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
    Gomperts SN; Locascio JJ; Makaretz SJ; Schultz A; Caso C; Vasdev N; Sperling R; Growdon JH; Dickerson BC; Johnson K
    JAMA Neurol; 2016 Nov; 73(11):1334-1341. PubMed ID: 27654968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo retention of
    Smith R; Schöll M; Widner H; van Westen D; Svenningsson P; Hägerström D; Ohlsson T; Jögi J; Nilsson C; Hansson O
    Neurology; 2017 Aug; 89(8):845-853. PubMed ID: 28754841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
    Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Schöll M; Ossenkoppele R; Strandberg O; Palmqvist S; ; Jögi J; Ohlsson T; Smith R; Hansson O
    Brain; 2017 Sep; 140(9):2286-2294. PubMed ID: 29050382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.
    Utianski RL; Whitwell JL; Schwarz CG; Senjem ML; Tosakulwong N; Duffy JR; Clark HM; Machulda MM; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Cortex; 2018 Feb; 99():358-374. PubMed ID: 29353121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Synaptic Loss in β-Amyloid Positive Versus β-Amyloid Negative Corticobasal Syndrome.
    Holland N; Savulich G; Jones PS; Whiteside DJ; Street D; Swann P; Naessens M; Malpetti M; Hong YT; Fryer TD; Rittman T; Mulroy E; Aigbirhio FI; Bhatia KP; O'Brien JT; Rowe JB
    Mov Disord; 2024 Jul; 39(7):1166-1178. PubMed ID: 38671545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Ali F; Whitwell JL; Martin PR; Senjem ML; Knopman DS; Jack CR; Lowe VJ; Petersen RC; Boeve BF; Josephs KA
    J Neurol; 2018 May; 265(5):1079-1088. PubMed ID: 29497818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
    Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
    Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between tau PET and retrospective cortical thinning in clinically normal elderly.
    LaPoint MR; Chhatwal JP; Sepulcre J; Johnson KA; Sperling RA; Schultz AP
    Neuroimage; 2017 Aug; 157():612-622. PubMed ID: 28545932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates.
    Ling H; Gelpi E; Davey K; Jaunmuktane Z; Mok KY; Jabbari E; Simone R; R'Bibo L; Brandner S; Ellis MJ; Attems J; Mann D; Halliday GM; Al-Sarraj S; Hedreen J; Ironside JW; Kovacs GG; Kovari E; Love S; Vonsattel JPG; Allinson KSJ; Hansen D; Bradshaw T; Setó-Salvia N; Wray S; de Silva R; Morris HR; Warner TT; Hardy J; Holton JL; Revesz T
    Acta Neuropathol; 2020 Apr; 139(4):717-734. PubMed ID: 31950334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A disease-specific metabolic brain network associated with corticobasal degeneration.
    Niethammer M; Tang CC; Feigin A; Allen PJ; Heinen L; Hellwig S; Amtage F; Hanspal E; Vonsattel JP; Poston KL; Meyer PT; Leenders KL; Eidelberg D
    Brain; 2014 Nov; 137(Pt 11):3036-46. PubMed ID: 25208922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degradation of emotion processing ability in corticobasal syndrome and Alzheimer's disease.
    Kumfor F; Sapey-Triomphe LA; Leyton CE; Burrell JR; Hodges JR; Piguet O
    Brain; 2014 Nov; 137(Pt 11):3061-72. PubMed ID: 25227744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.